Thanh bên bài viết

PDF
Ngày xuất bản: 29/11/2024
Số lượt xem tóm tắt: 103
Số lượt xem PDF: 64
DOI: https://doi.org/10.51298/vmj.v544i2.11913
Số xuất bản
Tập 544 Số 2 (2024): Vietnam Medical Journal
Chuyên mục
Các bài báo
Trích dẫn bài báo
Pham , T. A., & Nguyen , P. A. (2024). SINGLE-AGENT TOPOTECAN IN PLATINUM-RESISTANT RECURRENT OVARIAN CANCER: A STUDY IN VIET NAM NATIONAL CANCER HOSPITAL. Tạp Chí Y học Việt Nam, 544(2). https://doi.org/10.51298/vmj.v544i2.11913

SINGLE-AGENT TOPOTECAN IN PLATINUM-RESISTANT RECURRENT OVARIAN CANCER: A STUDY IN VIET NAM NATIONAL CANCER HOSPITAL

Pham Tuan Anh1,, Nguyen Phuong Anh1
1 Optimal Clinical Care Department, National Cancer Hospital of Viet Nam

Nội dung chính của bài viết

Tóm tắt

Platinum-based doublet chemotherapy is still supposed as standard regimen in ovarian cancer. However, the rate of relapse or refractory is also very high and vary from 80-85% with stage III-IV ovarian cancer [1]. The prognosis of platinum-resistant ovarian cancer (relapse or refractory within 6 months after initial treatment) has a median survival of 9–12 months and less than 15% respond to subsequent chemotherapy [2]. Thesedays, there are several agents were introduced to control this disease such as Docetaxel, Etoposid, Gemcitabine, Liposomal doxorubicin with overall response rate vary from 12-27% [3] [4] [5]. The objective of this study was to evaluate response and toxicity of 5-day Topotecan chemotherapy in women with primary and secondary platinum-resistant epithelial ovarian cancer.

Chi tiết bài viết

Từ khóa

Topotecan, Ovarian Cancer, Platinum-Resistant

Tài liệu tham khảo

1. Thuan Tran Van et al. 2014, Diagnosis and Treatment of Cancer Diseases, Hanoi Medical Publishing House. 339-351.
2. Davis et al. 2014, “Platinum resistant” ovarian cancer: what is it, who to treat and how to measure benefit? Gynecologic Oncology 133.624–631.
3. Gordon AN, Granai CO, Róe PG et al. (2000). Phase II study of liposimal doxorubicin in platinum and paclitaxel refractory epithelial ovarian cancer. J Clin Oncol. 18, 3093-3097.
4. Rose PG, Blessing JA, Mayer SR et al. (1998). Prolonged oral etoposide as second line therapy for platinum resistent and platinum senstive ovarian cancer. A Gyecologic Oncology Group study. J Clin Oncol. 16, 405- 410.
5. Gordon AN, Fleage JT, Guthrie D, et al (2001). Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19
6. Bray F., Ferlay J., Soerjomataram I., et al. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 68(6), 394–424.
7. Peng LH, ChenXY, Wu TX, Topotecan for ovarian cancer. Cochrance Database Syst Rev 2008; CD00589
8. Jalid Sehouli, Dirk Stengel, Philipp Harter, et al (2010): Topotecan weekly versus Conventional 5- day schedule in patients with Platinum – resistant ovarian cancer: A randomized multicenter pha II trial of the north- Eastern German society of gynecological oncology ovarian cancer stady group. J Clin Oncol 29:242-248.
9. Bokkel Huinink W (1997), Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 1997 Jun;15(6):2183-93.
10. Gordon AN, Fleage JT, Guthrie D, et al (2001). Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19.